急性缺血性卒中患者血栓切除术的成本效益:THRACE随机对照试验
基于THRACE随机对照试验的个体水平数据,比较静脉溶栓联合机械取栓(IVMT)与单纯静脉溶栓(IVT)的经济性。结论认为IVMT相比单纯IVT具有成本效益。
要点
- IVMT较IVT提高90天功能独立率10.9%(53.0% vs 42.1%,P=0.028)。
- 敏感性分析中IVMT具有成本效益的概率在QALY维度为92.2%。
核心结论
- 基于随机对照试验数据,急性缺血性卒中采用IVMT治疗相比单纯IVT具有成本效益。
研究设计与样本
- THRACE随机对照试验(NCT01062698)的个体水平成本与结局数据分析,患者随机接受IVT或IVMT。
主要发现
- IVMT组(n=200)与IVT组(n=202)相比,90天功能独立率提高10.9%(53.0% vs 42.1%,P=0.028)。
- IVMT增加成本2116美元(1909欧元)。
- 死亡率无显著差异(12% vs 13%,P=0.70),症状性颅内出血无显著差异(2% vs 2%,P=0.71)。
- 敏感性分析中IVMT具有成本效益的概率:避免残疾维度84.1%,QALY维度92.2%。
临床怎么用
- 在随机试验证据支持下,IVMT治疗急性缺血性卒中在经济性上可被接受。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: The benefit of mechanical thrombectomy added to intravenous thrombolysis (IVT) in patients with acute ischemic stroke has been largely demonstrated. However, evidence of the economic incentive of this strategy is still limited, especially in the context of a randomized controlled trial. We aimed to analyze whether mechanical thrombectomy combined with IVT (IVMT) is cost-effective when compared with IVT alone. METHODS: Individual-level cost and outcome data were collected in the THRACE randomized controlled trial (Thrombectomie des Artères Cerébrales) including patients with acute ischemic stroke. Patients were assigned to receive IVT or IVMT. The primary outcomes were modified Rankin Scale score of functional independence at 90 days (score 0-2) and the EuroQol-5D quality-of-life score at 1 year. RESULTS: Treating acute ischemic stroke with IVMT (n=200) versus IVT (n=202) increased the rate of functional independence by 10.9% (53.0% versus 42.1%; P=0.028), at an increased cost of $2116 (€1909), with no significant difference in mortality (12% versus 13%; P=0.70) or symptomatic intracranial hemorrhage (2% versus 2%; P=0.71). The cost per one averted case of disability was estimated at $19 379 (€17 480). The incremental cost per one quality-adjusted life year gained was $14 881 (€13 423). On sensitivity analysis, the probability of cost-effectiveness with IVMT was 84.1% in terms of cases of averted disability and 92.2% in terms of quality-adjusted life years. CONCLUSIONS: Based on randomized trial data, this study demonstrates that IVMT used to treat acute ischemic stroke is cost-effective when compared with IVT alone. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT01062698.
引用
- Achit H, Soudant M, Hosseini K, et al. Cost-Effectiveness of Thrombectomy in Patients With Acute Ischemic Stroke: The THRACE Randomized Controlled Trial. Stroke. 2017. PMID: 28916667. doi:10.1161/STROKEAHA.117.017856
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。